手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| メタアナリシスによる第III相臨床試験× | ネットワークメタアナリシス× | |
|---|---|---|
| 分野≠ | 疫学 | エビデンス統合 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1976 (meta-analysis); systematic application to Phase III RCTs from 1990s onward | 2002 |
| 提唱者≠ | Glass, G. V. (meta-analysis formalized); applied to Phase III trials via Cochrane Collaboration (Chalmers, Altman, Higgins) | Lumley (2002) |
| 種類≠ | Systematic quantitative evidence synthesis | Method |
| 原典≠ | Whitehead, A. (2002). Meta-Analysis of Controlled Clinical Trials. Wiley. ISBN: 978-0471983705 | Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI ↗ |
| 別名≠ | Phase III meta-analysis, pooled Phase III analysis, systematic review of Phase III RCTs, confirmatory meta-analysis | Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis |
| 関連≠ | 3 | 1 |
| 概要≠ | A meta-analytic Phase III clinical trial is a systematic, quantitative synthesis of multiple Phase III randomized controlled trials (RCTs) examining the same intervention. By pooling confirmatory trial data under a pre-registered protocol, the approach yields more precise effect estimates, resolves conflicting findings across trials, and supports regulatory or clinical guideline decisions with the highest level of evidence available in the evidence hierarchy. | Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied. |
| ScholarGateデータセット ↗ |
|
|